课题基金 / 基金详情

Research Capacity Core

Research Capacity Core
研究能力核心
批准号:
10708009
负责人:
JOSIAH OCHIENG
金额:
$138.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
未结题
起止时间:
1997-09-30 至 2027-05-31

项目摘要

项目成果

JOSIAH OCHIENG的其他基金

相关文献

中文摘要
翻译
项目摘要。Meharry RCMI研究能力核心(MRRCC)的总体目标是增加 梅哈里医学院资助的研究人员数量为此,RCMI配备了设备和人员, MRRCC拥有最先进的生物医学仪器,使我们的研究人员能够在 与范德比尔特大学等研究密集型机构的研究人员平起平坐。MRRCC核心 董事们还与范德比尔特大学的同行建立了密切的工作关系, 我们的调查人员能够使用范德比尔特的设备,他们可能需要,但目前还没有 在Meharry例如,我们的研究人员可以访问和利用电子显微镜在范德比尔特为他们的 由于这种安排而产生的成像需求(见支持函)。在RCMI当前的供资周期内, 研究人员能够获得R 01,R21,SC 1和U 54-癌症治疗机构发起的资金, 在MRRCC中生成的数据。这些非RCMI赠款是在MRRCC的帮助下获得的, 超过1100万美元。MRRCC还促进了我们调查人员之间的合作。例如在 在当前的RCMI资助周期中,有314项基础科学资助申请与5个MRRCC中的至少一个合作 丹具体而言,65个应用程序与单核协作,50个与双核协作,54个与3核协作,37个与4核协作 8个与所有5个核心协作。在当前应用中,我们对MRRCC有两个广泛的具体目标: 目标1.扩大核心服务和资源。我们将用机构资金购买OpenSPR系统, 蛋白质-蛋白质相互作用的真实的时间和海马代谢组学研究。随着资金到位,我们 我们将继续根据用户的需求提供新的仪器。我们将建立一个新的基因组数据库, 核心该核心将提供下一代测序(NGS)数据分析,数据挖掘,AI/ML, 通过开发基因组数据库和最先进的数据访问门户网站实现可视化。最后,我们将 建立基因编辑服务新的核心服务将帮助用户设计CRISPR/Cas9 实验方案,进行转染/感染,确定CRISPR效率,克隆阳性细胞,和 评估在/脱靶效率。 目标2.继续提供优质服务。我们提供的服务被认为是产生 赠款的初步数据,在高影响力期刊上发表手稿,并使获得校外 给予支持。我们将加强业务运营。我们正在与我们的办公室建立直接联系, 信息技术(OIT),通过内部连接提供无缝数据跟踪并提高成本回收 制度层面。我们还将加强MRRCC子核心Meharry内的互联互通 研究部门和国家RCMI网络。我们会加强收回成本的工作, 资助研究人员每年至少为他们将从MRRCC获得的服务预算2,000美元。
英文摘要
Project Summary. The overarching goal of Meharry RCMI Research Capacity Core (MRRCC) is to increase the number of funded investigators at Meharry Medical College. To this end, RCMI has equipped and staffed MRRCC with the latest state of the art biomedical instrumentation that enables our investigators to compete on equal footing with investigators from research intensive institutions like Vanderbilt University. MRRCC Core directors have also established a close working relationship with their counterparts at Vanderbilt University such that our investigators are able to access equipment at Vanderbilt that they may need but not currently available at Meharry. For example, our investigators can access and utilize electron microscope at Vanderbilt for their imaging needs due to such arrangements (see letter of support). During the current funding cycle of RCMI, our investigators were able to obtain R01, R21, SC1 and U54-Cancer investigator-initiated funding based on the data generated in MRRCC. These non-RCMI grants that were obtained with the help of MRRCC totaled more than $ 11,000,000. MRRCC has also fostered collaboration among our investigators. For example, during the current RCMI funding cycle, 314 basic science grant applications collaborated with at least one of the 5 MRRCC cores. Specifically, 65 applications collaborated with one core, 50 with 2 cores, 54 with 3 cores, 37 with 4 cores and 8 collaborated with all the 5 cores. We have 2 broad specific aims for MRRCC in the current application: Aim 1. Expand core services and resources. We will purchase with institutional funds an OpenSPR system for protein-protein interactions in real time and Seahorse for metabolomics studies. As funds become available, we will continue to provide new instrumentation based on our user’s needs. We will establish a new Genomics Data Core. This core will provide Next Generation Sequencing (NGS) data analysis, data mining, AI/ML, and visualization through development of genomic databases and state-of-the-art data-access portal. Lastly we will establish Gene Editing Services. The new core service will help users with the design of CRISPR/Cas9 experimental protocols, perform transfection/infection, determine CRISPR efficiency, clone positive cells, and evaluate on/off-targets efficiency. Aim 2. Continue to provide high quality service. The services we provide are deemed necessary for generating preliminary data for grants, publishing manuscripts in high impact journals, and enabling acquisition of extramural grant support. We will enhance business operations. We are establishing direct connectivity with our Office of Information Technology (OIT) to provide seamless data tracking and improve cost recovery by connecting within institutional-level systems. We will also enhance interconnectivity within the MRRCC Sub-Cores, Meharry research departments, and the national RCMI network. We will enhance cost recovery efforts by requiring funded investigators to budget at least $ 2,000 per year for services that they will get from MRRCC.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Analysis of Serum Exsomes in Patients with Colorectal and Breast Cancer
  • 批准号:
    8261513
  • 项目类别:
  • 资助金额:
    $7.68万
  • 财政年份:
    2011
  • 负责人:
    JOSIAH OCHIENG
  • 依托单位:
Project 2 Fetuin-A in Prostate Cancer
  • 批准号:
    10327934
  • 项目类别:
  • 资助金额:
    $18.97万
  • 财政年份:
    2011
  • 负责人:
    JOSIAH OCHIENG
  • 依托单位:
Project 2 Fetuin-A in Prostate Cancer
  • 批准号:
    10705093
  • 项目类别:
  • 资助金额:
    $22.57万
  • 财政年份:
    2011
  • 负责人:
    JOSIAH OCHIENG
  • 依托单位:
Project 2 Fetuin-A in Prostate Cancer
  • 批准号:
    10493424
  • 项目类别:
  • 资助金额:
    $22.57万
  • 财政年份:
    2011
  • 负责人:
    JOSIAH OCHIENG
  • 依托单位: